Dyne Therapeutics Prices Upsized $375 Million Public Offering to Fuel Muscle Disease Pipeline

Dyne Therapeutics announced the pricing of an upsized $375 million public stock offering at $20.50 per share to advance DMD and DM1 programs and extend cash runway into 2029.